血清TK1在非小细胞肺癌辅助诊断中的临床意义
|
摘要
目的:探讨血清细胞质胸苷激酶1(TK1)在非小细胞肺癌(NSCLC)辅助诊断方面的临床应用价值。方法:运用免疫增强化学发光法(ECL)检测比较106例NSCLC患者、36例良性肺疾病患者和50例健康体检者的TK1水平,分析TK1单独及联合传统肿瘤标志物(CEA、NSE、CYFRA21-1和SCC-Ag)检测在非小细胞肺癌辅助诊断中的价值;并进一步分析TK1与NSCLC患者临床病理参数间的相关性。结果:NSCLC组患者TK1水平及阳性率显著高于良性肺疾病组和健康对照组(P <0. 05),而良性肺疾病组与健康对照组之间TK1水平差异无统计学意义(P> 0. 05); NSCLC患者TK1水平与性别、年龄、吸烟史和淋巴结转移状态无显著相关性;与患者的病理类型、分化程度、TNM分期和远处转移情况密切相关;各项肿瘤指标单独检测时,敏感性都不高,而五项联合检测则可将NSCLC的敏感性和准确性显著提高。结论:血清TK1作为一种新的肿瘤标志物,在肺癌的辅助诊断中具有潜在的应用价值。
Objective: To explore the clinical value of serum cytoplasmic thymidine kinase 1(TK1) in the diagnosis of nonsmall cell lung cancer(NSCLC). Methods: Immunohistochemical chemiluminescence(ECL) was used to detect and compare the TK1 levels in 106 NSCLC patients,36 benign lung disease patients,and 50 healthy subjects. Analyze the value of TK1 alone or in combination with traditional tumor markers(CEA,NSE,CYFRA21-1,and SCC-Ag) in the diagnosis of non-small cell lung cancer. And then study the correlation between TK1 level and clinicopathological features of NSCLC patients. Results: The level of TK1 and positive rate in NSCLC group were significantly higher than those in benign lung disease group and healthy control group(P < 0. 05),but there was no significant difference in TK1 level between benign lung disease group and healthy control group(P > 0. 05). There was no significant correlation between TK1 level and gender,age,smoking history and lymph node metastasis status in NSCLC patients; but it was closely related to the pathological type,differentiation degree,TNM stage and distant metastasis. Conclusion: As a new tumor marker,serum TK1 has potential application value in the auxiliary diagnosis of lung cancer.
Objective: To explore the clinical value of serum cytoplasmic thymidine kinase 1(TK1) in the diagnosis of nonsmall cell lung cancer(NSCLC). Methods: Immunohistochemical chemiluminescence(ECL) was used to detect and compare the TK1 levels in 106 NSCLC patients,36 benign lung disease patients,and 50 healthy subjects. Analyze the value of TK1 alone or in combination with traditional tumor markers(CEA,NSE,CYFRA21-1,and SCC-Ag) in the diagnosis of non-small cell lung cancer. And then study the correlation between TK1 level and clinicopathological features of NSCLC patients. Results: The level of TK1 and positive rate in NSCLC group were significantly higher than those in benign lung disease group and healthy control group(P < 0. 05),but there was no significant difference in TK1 level between benign lung disease group and healthy control group(P > 0. 05). There was no significant correlation between TK1 level and gender,age,smoking history and lymph node metastasis status in NSCLC patients; but it was closely related to the pathological type,differentiation degree,TNM stage and distant metastasis. Conclusion: As a new tumor marker,serum TK1 has potential application value in the auxiliary diagnosis of lung cancer.
引文
[1] Goldstraw P,Chansky K,Crowley J,et al. The IASLC Lung Cancer Staging Project:Proposals for Revision of the TNM Stage Groupings in the Forthcoming(Eighth)Edition of the TNM Classification for Lung Cancer[J]. J Thorac Oncol,2016,11(1):39-51.
[2] Sung SY,Kwak YK,Lee SW,et al. Lymphovascular Invasion Increases the Risk of Nodal and Distant Recurrence in Node-Negative Stage I-IIA Non-Small-Cell Lung Cancer[J]. Oncology,2018,95(3):156-162.
[3]李铭,胡广原,梅齐,等.晚期非小细胞肺癌化疗[J].实用临床医药杂志,2017,21(13):26-28.
[4] Torre LA,Bray F,Siegel RL,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.
[5] Malhotra J,Jabbour SK1 and Aisner J. Current state of immunotherapy for non-small cell lung cancer[J]. Transl Lung Cancer Res,2017,6(2):196-211.
[6] Antonelli G,Libra M,Panebianco V,et al. Molecular-targeted therapy for elderly patients with advanced non-small cell lung cancer[J].Oncol Lett,2016,11(1):3-8.
[7]卢兴兵,刘波,杨舒羽,等.血清标志物联合检测对非小细胞肺癌临床诊断的意义[J].标记免疫分析与临床,2018,25(7):958-962.
[8] Aufderklamm S,Todenh9fer T,Gakis G,et al. Thymidine kinase and cancer monitoring[J]. Cancer Lett,2012,316(1):6-10.
[9]刘鹏飞,姬舒荣.血清胸苷激酶1在恶性肿瘤筛查和复发转移监测中的研究进展[J].中华临床医师杂志:电子版,2013,7(23):10858-10860.
[10] Li Z,Wang Y,He J,et al. Serological thymidine kinase 1 is a prognostic factor in oesophageal,cardial and lung carcinomas[J]. Eur J Cancer Prev,2010,19(4):313-318.
[11] Brockenbrough JS,Morihara JK,Hawes SE,et al. Thymidine kinase1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation[J]. J Histochem Cytochem,2009,57(11):1087-1097.
[12] Li HX,Lei DS,Wang XQ,et al. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer[J]. Oncol Rep,2005,13(1):145-149.
[13]刘京生,刘桂华,杜昆,等.中国人群中血清TK1对不同恶性肿瘤诊断价值的Meta分析[J].山东大学学报:医学版,2015,53(9):71-79.
[14] Ning S,Wei W,Li J,et al. Clinical significance and diagnostic capacity of serum TK1,CEA,CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients[J]. J Cancer,2018,9(3):494-501.
[15] Jiang ZF,Wang M,Xu JL. Thymidine kinase 1 combined with CEA,CYFRA21-1 and NSE improved its diagnostic value for lung cancer[J]. Life Sci,2018,194:1-6.
[2] Sung SY,Kwak YK,Lee SW,et al. Lymphovascular Invasion Increases the Risk of Nodal and Distant Recurrence in Node-Negative Stage I-IIA Non-Small-Cell Lung Cancer[J]. Oncology,2018,95(3):156-162.
[3]李铭,胡广原,梅齐,等.晚期非小细胞肺癌化疗[J].实用临床医药杂志,2017,21(13):26-28.
[4] Torre LA,Bray F,Siegel RL,et al. Global cancer statistics,2012[J]. CA Cancer J Clin,2015,65(2):87-108.
[5] Malhotra J,Jabbour SK1 and Aisner J. Current state of immunotherapy for non-small cell lung cancer[J]. Transl Lung Cancer Res,2017,6(2):196-211.
[6] Antonelli G,Libra M,Panebianco V,et al. Molecular-targeted therapy for elderly patients with advanced non-small cell lung cancer[J].Oncol Lett,2016,11(1):3-8.
[7]卢兴兵,刘波,杨舒羽,等.血清标志物联合检测对非小细胞肺癌临床诊断的意义[J].标记免疫分析与临床,2018,25(7):958-962.
[8] Aufderklamm S,Todenh9fer T,Gakis G,et al. Thymidine kinase and cancer monitoring[J]. Cancer Lett,2012,316(1):6-10.
[9]刘鹏飞,姬舒荣.血清胸苷激酶1在恶性肿瘤筛查和复发转移监测中的研究进展[J].中华临床医师杂志:电子版,2013,7(23):10858-10860.
[10] Li Z,Wang Y,He J,et al. Serological thymidine kinase 1 is a prognostic factor in oesophageal,cardial and lung carcinomas[J]. Eur J Cancer Prev,2010,19(4):313-318.
[11] Brockenbrough JS,Morihara JK,Hawes SE,et al. Thymidine kinase1 and thymidine phosphorylase expression in non-small-cell lung carcinoma in relation to angiogenesis and proliferation[J]. J Histochem Cytochem,2009,57(11):1087-1097.
[12] Li HX,Lei DS,Wang XQ,et al. Serum thymidine kinase 1 is a prognostic and monitoring factor in patients with non-small cell lung cancer[J]. Oncol Rep,2005,13(1):145-149.
[13]刘京生,刘桂华,杜昆,等.中国人群中血清TK1对不同恶性肿瘤诊断价值的Meta分析[J].山东大学学报:医学版,2015,53(9):71-79.
[14] Ning S,Wei W,Li J,et al. Clinical significance and diagnostic capacity of serum TK1,CEA,CA 19-9 and CA 72-4 levels in gastric and colorectal cancer patients[J]. J Cancer,2018,9(3):494-501.
[15] Jiang ZF,Wang M,Xu JL. Thymidine kinase 1 combined with CEA,CYFRA21-1 and NSE improved its diagnostic value for lung cancer[J]. Life Sci,2018,194:1-6.